Myopia Control with Myproclear Red Light Therapy

Myproclear;   Repeated Low-Level Red-Light (RLRL) therapy

        Advanced myopia control made early, easy and effective ; Exclusive to Shattky Optometrists Hastings and Waipukurau‍

Myopia is expected to affect one in two people by 2050, becoming one of the world’s leading causes of permanent blindness.

Eyerising International is leading the effort to slow the progression of childhood myopia with its original, patented and clinically validated at-home myopia red-light therapy device, the Myproclear.

Saving sight sooner makes brighter futures.

Using our innovative, patented technology to deliver repeated Low-Level Red-Light (RLRL) therapy, the Myproclear gently stimulates the body’s own healing mechanisms to address the underlying issues that cause myopia.

Features and Benefits;

• Non-invasive
• No drugs, no injections, no specialised lenses and no risk of infection
• No known significant side effects;
• Suitable and easily tolerated by children as young as 3 - 16 years of age
• Highly effective myopia control therapy with up to 87.7% treatment efficacy3 minute treatment, 2 times per day, 5 days per week, with a minimum of 4 hours between sessions
• Treatment administered at home – delivering high compliance and over 80% patient loyalty
• Adjunct therapy potential with strong synergy for patients who are not responding to Ortho-K
• Comprehensive patient compliance data provided to clinicians enabling superior assessment and efficacy.

‍Note; The Myproclear has been cleared as a medical device by the following regulators: CE (EU), Medsafe (NZ) and MHRA (UK).Eyerising International is ISO 13485:2016 certified by notified body BSI.